MiNK Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $48.02M
- P/E (TTM)
- –
- Dividend yield
- –
About MiNK Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing allogeneic invariant natural killer T cell therapies. The company advances both native and genetically engineered cell therapies to address cancer and immune-mediated conditions, including critical pulmonary immune failure and graft-versus-host disease. Its pipeline features agenT-797, an off-the-shelf native cell therapy evaluated across solid tumors and acute respiratory distress conditions, alongside preclinical engineered programs such as MiNK-413 and MiNK-215. Target patient groups comprise individuals with refractory solid tumors, acute hypoxemic respiratory failure, severe pneumonia, and transplant recipients facing alloreactive immune complications.
The company operates an in-house, closed-system current Good Manufacturing Practice manufacturing facility in Lexington, Massachusetts to produce allogeneic therapies at scale. In addition to its manufacturing operations in Massachusetts, the business maintains its principal executive offices in New York, New York.
Summary of the business section of MiNK Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MiNK Therapeutics, Inc.
- Headquarters
- New York, NY
- Address
- 149 Fifth Avenue, Suite 500 10010
- Phone
- (212) 994-8250
- Website
- minktherapeutics.com
- Employees
- 15, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- INKT
- Exchange
- Nasdaq
- IPO date
- Oct 15, 2021
- Shares outstanding
- 5M, Aug 11, 2026
- Public float
- $10.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Jan 28, 2025; 1-for-10 reverse, Jan 28, 2025
- SEC CIK
- 1840229
- CUSIP
- 603693201
- ISIN
- US6036932019
- LEI
- 529900Z7778N8ZY89B90
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Melissa Orilall | Principal Financial Officer | 222 |
| Austin Charette | Principal Accounting Officer | 40 |
| Jennifer Buell | Chief Executive Officer | 57,942 |
| Brian Corvese | Director | 54,770 |
| John Bradley Holcomb | Director | 4,691 |
| Ulf Wiinberg | Director | 51,759 |
| Barbara Ryan | Director | 23,591 |
| Peter Behner | Director | 24,404 |
| Robert Peter Kadlec | Director | 19,126 |
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 15 full-time employees, 33% of whom have Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 13, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 30, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 29, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 15, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 13, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 18, 2021 | Name change | Name changed from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc. |